Identification of (poly)phenol treatments that modulate the release of pro-inflammatory cytokines by human lymphocytes

Christopher T. Ford1†, Siân Richardson1†, Francis McArdle1, Silvina B. Lotito2, Alan Crozier3, Anne McArdle1 and Malcolm J. Jackson1∗

1Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool L7 8TX, UK
2Unilever, Colworth Science Park, Sharnbrook, Bedford MK44 1LQ, UK
3Department of Nutrition, University of California, Davis, CA 95616, USA

(Submitted 23 July 2015 – Final revision received 22 January 2016 – Accepted 12 February 2016 – First published online 17 March 2016)

Abstract

Diets rich in fruits and vegetables (FV), which contain (poly)phenols, protect against age-related inflammation and chronic diseases. T-lymphocytes contribute to systemic cytokine production and are modulated by FV intake. Little is known about the relative potency of different (poly)phenols in modulating cytokine release by lymphocytes. We compared thirty-one (poly)phenols and six (poly)phenol mixtures for effects on pro-inflammatory cytokine release by Jurkat T-lymphocytes. Test compounds were incubated with Jurkat cells for 48 h at 1 and 30 μM, with or without phorbol ester treatment at 24 h to induce cytokine release. Three test compounds that reduced cytokine release were further incubated with primary lymphocytes at 0.2 and 1 μM for 24 h, with lipopolysaccharide added at 5 μg. Cytokine release was measured, and generation of H2O2 by test compounds was determined to assess any potential correlations with cytokine release. A number of (poly)phenols significantly altered cytokine release from Jurkat cells (P < 0.05), but H2O2 generation did not correlate with cytokine release. Resveratrol, isorhamnetin, curcumin, vanillic acid and specific (poly)phenol mixtures reduced pro-inflammatory cytokine release from T-lymphocytes, and there was evidence for interaction between (poly)phenols to further modulate cytokine release. The release of interferon-γ induced protein 10 by primary lymphocytes was significantly reduced following treatment with 1 μM isorhamnetin (P < 0.05). These results suggest that (poly)phenols derived from onions, turmeric, red grapes, green tea and açai berries may help reduce the release of pro-inflammatory mediators in people at risk of chronic inflammation.

Key words: Jurkat cells; Curcumin; Resveratrol; Isorhamnetin; TNFα

(Poly)phenols, comprising flavonoids and related compounds, are produced by plants that are widely consumed in the human diet. A high dietary intake of fruits and vegetables, which are rich in (poly)phenols, has been linked through epidemiological studies with reduced risk for diseases that are associated with age-related chronic inflammation, including cardiovascular disease (1–5), type II diabetes (4,5), cancer (6–9), Alzheimer’s disease (10) and Parkinson’s disease (11). Supplementation with (poly)phenol-rich foods or purified (poly)phenols has been reported to reduce levels of pro-inflammatory cytokines in the human circulation, including TNFα and IL-6, cytokines that have been implicated in the pathogenesis of chronic inflammatory diseases (12–14). T-lymphocytes significantly contribute to the release of pro- and anti-inflammatory cytokines both into the circulation and within tissues. Dietary (poly)phenols may influence the behaviour of T-lymphocytes and other cells via redox signalling, that is the production or quenching of free radicals, or by interactions with specific proteins (15). The production of H2O2 by (poly)phenols through autoxidation catalysed by transition metals is known to influence the behaviour of cells in culture (16,17), but the effects of (poly)phenol-induced H2O2 generation on T-lymphocytes and the relevance of this in the modulation of cytokine release are not well understood. A majority of (poly)phenols have low bioavailability in vivo as parent compounds (18,19); therefore, recent interest has been focused on metabolites of dietary (poly)phenols, including the methylated, glucuronidated, and sulphated conjugates that are produced by intestinal and liver cells, and the aromatic acids produced by the colonic bacterial flora (20–22).

We aimed to compare thirty-one individual (poly)phenols for their effects on the release of inflammatory cytokines by Jurkat CD4+ T-lymphocytes. We examined some key dietary (poly)
phenols and a number of metabolites, including specifically a substantial number of low molecular weight colonic catecholamines. Following this initial screen, three anti-inflammatory compounds were selected for further investigation of their effects on cytokine release by primary peripheral blood mononuclear cell (PBMC)-derived human lymphocytes. We further aimed to assess the generation of \( \text{H}_2\text{O}_2 \) in cell culture media by these (poly)phenols and to assess whether \( \text{H}_2\text{O}_2 \) generation significantly influences cytokine release or growth of Jurkat CD4\(^+\) T-lymphocytes in \textit{vitro}. The question of the most appropriate doses of (poly)phenols to be used in \textit{vitro} studies is controversial within the field. Following dietary intake, (poly)phenols and the individual metabolites/catabolites can be detected in the circulation with \( C_{\text{min}} \) values generally at ns or low \( \mu \text{M} \) concentrations, whereas following supplementation with purified compounds or enriched food extracts values of up to 20–50 \( \mu \text{M} \) have been reported. For an individual with a typical dietary intake of multiple fruits and vegetables, numerous (poly)phenol metabolites/catabolites coexist in the circulation at any one time. Whether mixtures of different (poly)phenols, each present at low doses, interact in their effects on cytokine release by lymphocytes has not been clear. We therefore also investigated the effects of six different mixtures of (poly)phenols on the release of pro-inflammatory cytokines by Jurkat T-lymphocytes, in order to determine whether multiple (poly)phenols at lower doses have additive or potentially synergistic effects compared with those of single (poly)phenols.

**Methods**

**Chemicals and materials**

Reagents were purchased from Sigma-Aldrich unless stated otherwise. Sigma-Aldrich also supplied resveratrol, quercetin, isorhamnetin, 3-O-methylquercetin, curcumin, (3\'-epigallocatechin-3-O-gallate, pelargonidin-3-O-glucoside, cyanidin-3-O-glucoside, chlorogenic acid (5-Ocaffeoylquinic acid), punicalagin, phloroglucinol (1,3,5-trihydroxybenzene), pyrogallol (1,2,3-trihydroxybenzene), catechol (1,2-dihydroxynaphthalene), protocatechuic acid (3,4-dihydroxybenzoic acid), 4-hydroxybenzoic acid, homoprotocatechuic acid (3',4'-dihydroxyphenylacetic acid), vanillic acid (3-methoxy-4-hydroxybenzoic acid), homovanillic acid (3'-methoxy-4'-hydroxyphenylacetic acid), 4'-hydroxyphenylacetic acid, 4'-hydroxymandelic acid, 5(3'-hydroxyphenyl) propionic acid, 3(4'-hydroxyphenyl) lactic acid, caffeic acid, dihydrocaffeic acid (3-C3', 4'-dihydroxyphenyl propionic acid), ferulic acid, isoforonic acid, dihydroferulic acid (3-C3'-methoxy-4'-hydroxyphenyl) propionic acid), hippoc acid and tyrosol, 4'-Hydroxyhippuric acid was obtained from Bachem Ltd. Feruloylglycine and isoferuloylglycine were generous gifts from Professor Takao Yokota (Teikyo University). Fig. 1 shows the structures of the compounds tested and highlights the metabolic relationships between the compounds.

**Cell culture and treatments**

Jurkat E6-1 human CD4\(^+\) T-lymphocytes obtained from the Health Protection Authority, UK, were cultured routinely at 37°C in a humidified 5% CO\(_2\) incubator in Roswell Park Memorial Institute (RPMI)-1640 medium containing phenol red supplemented with 10% fetal bovine serum (FBS) and 2 ms-L-glutamine. Jurkat cells were seeded at 2 \times 10^6 cells/ml in a forty-eight-well plate (500 \muL culture volume) and treated with each test compound at 1 or 30 \muM by dilution from 5 \muM stocks in dimethyl sulfoxide (DMSO). The same volume of DMSO only was added to vehicle control wells. After 24 h of incubation with test compounds, 25 mg/ml phorbol 12-myristate 13-acetate (PMA) by 1:1000 dilution from a 25 \mug/ml DMSO stock solution and 5 \muM/ml phytohaemagglutinin (PHA) by 1:1000 dilution from a 5 mg/ml stock solution in water were added to some wells, and vehicle controls were treated with DMSO at 1:1000 dilution. Typically, the equivalent volume of DMSO added to each well was 0.5 \muL. Co-treatment with PMA (a protein kinase C activator) and PHA (a T-cell receptor cross-linking agent) has been widely used to stimulate cytokine production by T-lymphocytes\(^{22}\). Following PMA/PHA treatment, plates were incubated for 24 h at 37°C and 5% CO\(_2\). Test compounds were not removed during PMA/PHA treatment, and thus the total incubation period with each (poly)phenol was 48 h. Each treatment was performed in quadruplicate alongside matched vehicle controls. Mixed (poly)phenol treatments were conducted using the same protocol, except that each of the four compounds in each mixture was added at either 0.25 or 7.5 \muM, thus achieving either a 1 or 30 \muM total concentration of (poly)phenols.

**Measurement of viable cell number**

Following incubations with test compounds and stimulation agents, cell numbers were quantified by transferring 100 \muL cell suspension from each well to a flat-bottomed, clear, ninety-six-well plate. A sample of 20 ml of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt and phenazine methosulfate reagent (Promega) was added to each well and the plate was incubated for 90 min at 37°C and 5% CO\(_2\). Following incubation, absorbance was read at 490 nm on a BMG Labtech Spectrostar Nano plate reader. Viable cell numbers were estimated from a standard curve determined by haemocytometer counting with 0.02% (w/v) trypan blue stain.

**Primary lymphocyte isolation, cell culture and treatment**

Primary human lymphocytes were obtained from a healthy 45-year-old female donor after obtaining written consent, by withdrawal of 50 ml blood from the antecubital vein using a butterfly needle and syringe. The procedure was approved by the National Research Ethics service, UK (reference 11/NW/0313), as well as by the University of Liverpool and Royal Liverpool and Broadgreen University Hospitals NHS Trust ethics committees. Whole blood was separated over Ficoll-Paque Premium density gradient medium (GE Healthcare Life Sciences) by centrifugation at 370 \textbf{g} for 30 min without rotor braking. PBMC were isolated from the buffy layer, centrifuged again at 370 \textbf{g} for 10 min without rotor braking, then resuspended in FBS containing 10% DMSO and cryogenically stored. The PBMC were later thawed, washed once in medium...
(RPMI-1640 supplemented with 10% FBS and 2 mmol/l of L-glutamine) to remove DMSO, resuspended in the same medium and then cultured at 37°C and 5% CO2 in a T25 tissue culture flask laid horizontally. After 5 d of incubation to allow monocytes to adhere to the culture flask, the lymphocyte-enriched suspension cells were seeded to a forty-eight-well plate at 2 × 10⁶ cells/ml in 150 µl total volume. After 24 h of incubation at 37°C/5% CO2, the lymphocytes were treated with test compounds (resveratrol, isorhamnetin and curcumin) diluted from 5 mmol/l DMSO stocks to a final concentration of either 0·2 or 1 µmol/l, or the same volume of DMSO only as the vehicle control. Lymphocytes were incubated for 5 h at 37°C/5% CO2; next, 20 ng/ml lipopolysaccharide (LPS) was added without removing media and the cells were incubated for a further 19 h. Following the total 24 h of incubation, cell numbers and viability were determined by trypan blue staining.

Unconjugated polyphenols

Polyphenol glucosides

Methylated and carboxylated polyphenols

Phenolic acids

![Diagram of polyphenols and their metabolites]
(0-02% w/v final concentration trypan blue; TC-20 automated cell counter, Bio-Rad) and media were harvested for quantification of cytokines.

**Quantification of cytokines in lymphocyte cell culture media**

Cells were pelleted by centrifugation at 400 \( g \) for 5 min. The culture media supernatants were immediately frozen at \(-80^\circ C\) and remained frozen until they were thawed for analysis using a Bioplex 200 multi-protein analysis platform (Bio-Rad) and Bioplex bead sets targeting the human cytokine analytes detailed in Table 1. The analysis was performed according to the manufacturer’s instructions. All reagents were purchased from Bio-Rad.

Cytokine concentrations were calculated by comparing raw fluorescence emission values with a standard curve diluted from a solution of mixed recombinant cytokine proteins (Bio-Rad). Cytokine concentrations were then normalised for the number of viable cells in the culture at the end of treatment, as quantified by trypan blue exclusion assay. Each time a Jurkat cell treatment experiment was performed, four test compounds were assayed together with a matched vehicle control (either DMSO alone or DMSO with PMA/PHA stimulation at 24 h, as appropriate). Data were normalised to yield percentage changes from vehicle controls by dividing values measured from (poly)phenol-treated cells by the value measured from the matched vehicle control and multiplying by 100. To ascertain whether mixtures of (poly)phenols may synergistically modulate Jurkat T-lymphocyte cytokine release, six mixtures were analysed, each comprised of four (poly)phenols. The results obtained following treatment of Jurkat T-lymphocytes with the (poly)phenol mixtures were compared with the averaged effects of those individual compounds. The total concentration of mixed (poly)phenols and their metabolites was constant at 1 or 30 \( \mu \)mol/l to enable closer comparison with the individual compound treatments.

**Luminescent plate reader analysis of \( \text{H}_2\text{O}_2 \) generation**

Using an opaque, black, ninety-six-well plate, 5 \( \mu \)l-DMSO stock solutions of thirty-two different (poly)phenols (the same thirty-one compounds tested for anti-inflammatory effects in the Jurkat cell model, plus homovanillic acid) were diluted to a final concentration of 30 \( \mu \)mol in 200 \( \mu \)l of working solution (1:1 solution of RPMI-1640 and Amplex Red (10-acetyl-3,7-dihydroxyphenoxazine)-HRP reagent; Invitrogen). A DMSO-only control was used as blank. Fluorescence was measured at 5-min intervals for 24 h with a Fluostar Omega plate reader (Bio-Tek Instruments) and converted into the rates of \( \text{H}_2\text{O}_2 \) generation (nmol/min) because of the relative magnitude of their induction by PMA/PHA treatment and the well-defined roles of each of these proteins as physiologically important pro-inflammatory cytokines.

**Statistical analysis**

Statistical analyses were performed using SPSS version 20 (IBM) using raw data for cell number and \( \text{H}_2\text{O}_2 \) generation and data normalised to cell number for cytokine measurements. Jurkat CD4\(^+\) T-lymphocytes and primary PBMC-derived lymphocytes treated with (poly)phenols were compared with matched vehicle controls by one-way ANOVA with Dunnett’s post hoc test. The predicted effects of mixtures of test compounds on cytokine release by Jurkat CD4\(^+\) T-lymphocytes were compared with the observed effects by one-way ANOVA with Tukey’s post hoc test. All the statistical tests were performed at \( \alpha = 0.05 \).

**Results**

**Phorbol 12-myristate 13-acetate/phytohaemagglutinin 24-h treatment stimulates the release of pro-inflammatory cytokines by Jurkat CD4\(^+\) T-lymphocytes**

Jurkat CD4\(^+\) T-lymphocytes were treated with the protein kinase C activator PMA and the plant-derived lymphocyte mitogen PHA for 24 h to induce an inflammatory response and cytokine release. The PMA/PHA-stimulated cells showed a significant increase in the release of several pro-inflammatory cytokines compared with vehicle control treatments (Table 1). We chose to focus on IL-2, IL-8 and TNF\(\alpha\) for further experiments because of the relative magnitude of their induction by PMA/PHA treatment and the well-defined roles of each of these proteins as physiologically important pro-inflammatory cytokines.

**Polyphenol catabolites modulate growth and cytokine release by Jurkat CD4\(^+\) T-lymphocytes**

After treatment with colonic catabolites of polyphenols (phenolic acids) for 48 h, we measured the density of viable Jurkat CD4\(^+\) T-lymphocytes in culture and the concentrations of the pro-inflammatory cytokines IL-2, IL-8 and TNF\(\alpha\) in the cell culture media. Comparisons between (poly)phenol treatments and vehicle controls revealed multiple effects on growth and cytokine release (Table 2). The low molecular weight (110–139 g/mol) catabolites catechol, phloroglucinol and 4-hydroxybenzoic acid caused significant declines in cell number (\(P < 0.05\); one-way ANOVA with Dunnett’s post hoc test) and significantly induced release of IL-2 and TNF\(\alpha\) (\(P < 0.05\); one-way ANOVA with Dunnett’s post hoc test), whereas tyrosol significantly decreased IL-2 and IL-8 release from non-stimulated cells at 1 \( \mu \)mol/l (\(P < 0.05\); one-way ANOVA with Dunnett’s post hoc test). Mid-molecular weight catabolites (168–195 g/mol) reduced pro-inflammatory cytokine release, with significant reduction in IL-2 release from non-stimulated cells by 1 \( \mu \)mol/l 4’-hydroxymandelic acid and vanillic acid (\(P < 0.05\); one-way ANOVA with Dunnett’s post hoc test). Higher molecular weight catabolites (196–252 g/mol) showed mixed effects: feruloylglycine at 1 \( \mu \)mol/l significantly increased the release of IL-2 and TNF\(\alpha\), and isoferuloylglycine at 30 \( \mu \)mol/l significantly reduced IL-8 release from PMA/PHA-stimulated Jurkat CD4\(^+\) T-lymphocytes (\(P < 0.05\); one-way ANOVA with Dunnett’s post hoc test).
T-lymphocytes (Fig. 3). Three polyphenols – resveratrol, isorhamnetin and curcumin – significantly reduced pro-inflammatory cytokine release at both 1 and 30 µmol/l and in both unstimulated and PMA/PHA-stimulated cells (P < 0.05; one-way ANOVA with Dunnett’s post hoc test). Curcumin treatment at 30 µmol/l led to the greatest reductions in pro-inflammatory cytokine release, with IL-2 release decreased by 96% and TNFα release ablated to undetectable Data key

IL-2 IL-8 TNFα

Cell number

+ PMA+ PMA+ PMA+ PMA+ PMA

Treatment

Catechol

1 µM

30 µM

Phloroglucinol

1 µM

30 µM

Pyrogallol

1 µM

30 µM

Tyrosol

1 µM

30 µM

4-Hydroxybenzoic acid

1 µM

30 µM

4'-Hydroxymandelic acid

1 µM

30 µM

Protocatechuic acid

1 µM

30 µM

Vanillic acid

1 µM

30 µM

Feruloylglycine

1 µM

30 µM

Isoferuloylglycine

1 µM

30 µM

Fig. 2. Heat map showing the effects of phenolic acids on cytokine release and growth by Jurkat CD4+ T-lymphocytes. Compounds are ordered by molecular weight from the lowest weight (top) to the highest weight (bottom). Data are presented as percentage differences from matched vehicle controls following 48h of treatment. Treatment and control experiments were performed with or without 25 ng/ml phorbol 12-myristate 13-acetate (PMA) and 5 µg/ml phytohaemagglutinin (PHA) stimulation at 24 h. TNFα could not be measured in the absence of PMA/PHA stimulation. * Mean value was significantly different compared with vehicle controls (P < 0.05; one-way ANOVA with Dunnett’s post hoc test). No significant effects were observed following treatment with caffeic acid, ferulic acid, isoferulic acid, 5-(3'-hydroxyphenyl) propionic acid, 5-(3',4'-dihydroxyphenyl) propionic acid, 5-(3'-methoxy-4'-hydroxyphenyl) propionic acid, homoprotocatechuic acid, 3-(4'-hydroxyphenyl) lactic acid, hippuric acid or 4'-hydroxyhippuric acid. Examples of the data from which these heat maps are derived are provided in the online Supplementary data to allow an assessment of the variability observed in these studies.

Table 1. Cytokines induced by phorbol 12-myristate 13-acetate/phytohaemagglutinin (PMA/PHA) treatment of Jurkat CD4+ T-lymphocytes (Mean values with their standard errors)

<table>
<thead>
<tr>
<th>Cytokines</th>
<th>Untreated control (pg/ml)</th>
<th>DMSO vehicle control (pg/ml)</th>
<th>24 h PMA/PHA stimulated (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SEM</td>
<td>Mean</td>
</tr>
<tr>
<td>Eotaxin-1</td>
<td>ND</td>
<td></td>
<td>2.85</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>ND</td>
<td></td>
<td>ND</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>ND</td>
<td></td>
<td>ND</td>
</tr>
<tr>
<td>IL-1β</td>
<td>ND</td>
<td></td>
<td>1.39</td>
</tr>
<tr>
<td>IL-2</td>
<td>13.45</td>
<td>1.39</td>
<td>14.40</td>
</tr>
<tr>
<td>IL-4</td>
<td>21.55</td>
<td>0.35</td>
<td>0.80</td>
</tr>
<tr>
<td>IL-6</td>
<td>ND</td>
<td></td>
<td>34.22</td>
</tr>
<tr>
<td>IL-7</td>
<td>0.3</td>
<td>0.06</td>
<td>ND</td>
</tr>
<tr>
<td>IL-8</td>
<td>35.25</td>
<td>2.88</td>
<td>34.22</td>
</tr>
<tr>
<td>IL-12p70</td>
<td>ND</td>
<td></td>
<td>ND</td>
</tr>
<tr>
<td>MCP-1</td>
<td>ND</td>
<td></td>
<td>ND</td>
</tr>
<tr>
<td>TNFα</td>
<td>ND</td>
<td></td>
<td>ND</td>
</tr>
</tbody>
</table>

GM-CSF, granulocyte macrophage-colony stimulating factor; IFN, interferon; MCP, monocyte chemoattractant protein. * P < 0.05 compared with DMSO vehicle control.
concentrations in PMA/PHA-stimulated cells (P < 0.05; one-way ANOVA with Dunnett’s post hoc test). The flavan-3-ol (−)-epigallocatechin-3-O-gallate, and the anthocyanins pelargonidin-3-O-glucoside and cyanidin 3-O-glucoside, significantly promoted the growth of Jurkat CD4+ T-lymphocytes at 1 µmol/l (P < 0.05; one-way ANOVA with Dunnett’s post hoc test). Chlorogenic acid and 3-O-methylquercetin showed some anti-proliferative effects on Jurkat CD4+ T-lymphocytes under all treatment conditions, although statistical significance was only achieved for the effects of 3-O-methylquercetin (P < 0.05; one-way ANOVA with Dunnett’s post hoc test).

Mixtures of (poly)phenols interact to modulate cytokine release

To assess potential interactions between test compounds in modulating cytokine release, we prepared several mixtures of (poly)phenols: mixture 1 representing low-molecular weight colonic catabolites such as catechol, chlorogluconol, 4-hydroxybenzoic acid and protocatechuic acid; mixture 2 representing mid-molecular weight colonic catabolites such as 4′-hydroxymandelic acid, 4′-hydroxyphenylacetic acid, 5-(3′-hydroxyphenyl) propionic acid and 3-(4′-hydroxyphenyl) lactic acid; mixture 3 representing a mixture of dietary polyphenols such as (−)-epigallocatechin-3-O-gallate, pelargonidin-3-O-glucoside, cyanidin-3-O-glucoside and punicalagin; mixture 4 representing polyphenols and high molecular weight hydroxycinnamate metabolites, such as dihydroferulic acid, feruloylglycine, quercetin and 3′-methylquercetin; mixture 5 representing a mixture of hydroxycinnamate derivatives derived from chlorogenic acid after the consumption of coffee, such as caffeic acid, ferulic acid, isoferulic acid and isoferuloylglycine; and mixture 6 representing compounds derived from apple cider, such as hippuric acid, tyrosol, 4′-hydroxyhippuric acid and chlorogenic acid. We measured cytokine release from Jurkat CD4+ T-lymphocytes following 48 h of incubation with each mixture at a total concentration of 1 or 30 µmol/l, with or without stimulation with PMA/PHA at 24 h. For comparison, the results previously obtained for cytokine release following treatment with each individual compound were averaged to generate a prediction of the effects expected if there were no interactions between compounds (i.e. a null hypothesis that there were no synergistic effects). The results illustrated in Fig. 4 indicate that five of the six test mixtures significantly reduced pro-inflammatory cytokine release in comparison with results anticipated from simple addition of the effects observed for individual compounds (P < 0.05; one-way ANOVA with Dunnett’s post hoc test).

<table>
<thead>
<tr>
<th>Treatment</th>
<th>µM</th>
<th>IL-2 (− PMA + PMA)</th>
<th>IL-8 (− PMA + PMA)</th>
<th>TNFα (− PMA + PMA)</th>
<th>Cell number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resveratrol</td>
<td>1 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+6–29%</td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+81–100%</td>
</tr>
<tr>
<td>Quercetin</td>
<td>1 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+6–29%</td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+81–100%</td>
</tr>
<tr>
<td>Isorhamnetin</td>
<td>1 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+6–29%</td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+81–100%</td>
</tr>
<tr>
<td>3-O-Methylergenidin</td>
<td>1 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+6–29%</td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+81–100%</td>
</tr>
<tr>
<td>Chlorogenic acid</td>
<td>1 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+6–29%</td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+81–100%</td>
</tr>
<tr>
<td>Curcumin</td>
<td>1 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+6–29%</td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+81–100%</td>
</tr>
<tr>
<td>(−)-Epigallocatechin-3-O-gallate</td>
<td>1 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+6–29%</td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+81–100%</td>
</tr>
<tr>
<td>Pelargonidin 3-O-glucoside</td>
<td>1 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+6–29%</td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+81–100%</td>
</tr>
<tr>
<td>Cyanidin 3-O-glucoside</td>
<td>1 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+6–29%</td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+81–100%</td>
</tr>
<tr>
<td>Punicalagin</td>
<td>1 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+6–29%</td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+81–100%</td>
</tr>
</tbody>
</table>
Anti-inflammatory polyphenols modulate cytokine release by peripheral blood mononuclear cell-derived human lymphocytes

We investigated the polyphenols resveratrol, isorhamnetin and curcumin, which had been identified to be the most effective in reducing cytokine release from among the panel of (poly)phenols that we screened in Jurkat CD4+ T-lymphocytes, to determine whether their inhibitory effects on pro-inflammatory cytokine release were sustained in PBMC-derived human lymphocytes (Fig. 5). The results suggest trends (i.e. \( P<0.09 \)) towards decreased IL-6, interferon-γ-induced protein 10 (IP-10) and TNFα release following treatment with resveratrol, isorhamnetin and curcumin at 0.2 or 1 µM. The reduction in IP-10 release after treatment with 1 µM isorhamnetin was statistically significant (\( P<0.05 \), one-way ANOVA with Dunnett’s post hoc test).

(Poly)phenols produce \( H_2O_2 \) in cell culture media

Some (poly)phenols have been reported to generate \( H_2O_2 \) in cell culture media. To quantify \( H_2O_2 \) production, we conducted kinetic spectrophotometry assays using Amplex red reagent, which is converted to fluorescent resorufin following oxidation by \( H_2O_2 \). Production of \( H_2O_2 \) was detected for sixteen of the thirty-two test compounds (Fig. 6(a)). \( H_2O_2 \) production was detected from the hydroxybenzene derivatives catechol and pyrogallol, the phenylacetic acid homoprotocatechuic acid, the hydroxycinnamates caffeic acid and dihydrocaffeic acid, and the ellagitannin punicalagin, whereas other test compounds produced no detectable levels of \( H_2O_2 \). Comparisons were also made to assess the effects of phenol red in the culture media, which showed that rates of \( H_2O_2 \) production were 24 (SEM 2) % lower in RPMI-1640 medium containing phenol red than in RPMI-1640 medium without phenol red (data not shown in detail).

Fig. 4. Heat maps showing cytokine release by Jurkat CD4+ T-lymphocytes following treatment with mixtures of four (poly)phenols at 1 or 30 µmol/l compared with vehicle controls (a), and mathematical averages of the effects on cytokine release following treatment with the individual compounds (b). Cells were incubated with (poly)phenol mixtures for 48 h, with or without the addition of 25 ng/ml phorbol myristoyl acetate and 5 µg/ml phytohaemagglutinin at the 24-h time point. The mixtures comprised the following: (1) catechol, phloroglucinol, 4-hydroxybenzoic acid and protocatechuic acid; (2) 4'-hydroxymandelic acid, 4-hydroxyphenylacetic acid, 5-(3'-hydroxyphenyl) propionic acid and 3-(4'-hydroxyphenyl) lactic acid; (3) (+)-epigallocatechin-3-O-gallate, pelargonidin-3-O-glucoside, cyanidin-3-O-glucoside and punicalagin; (4) dihydroferulic acid, feruloylglycine, quercetin and 3-O-methylquercetin; (5) caffeic acid, ferulic acid, isoflavone acid and isofeluraylglycine; and (6) hippuric acid, tyrosol, 4'-hydroxyhippuric acid and chlorogenic acid. * Mean value was significantly different between the ‘expected’ response predicted by mathematically averaging the effects of individual compounds and the ‘observed’ response measured following treatment with the mixtures (\( P<0.05 \); one-way ANOVA with Tukey’s post hoc test).

### Treatment and Cytokine Release

<table>
<thead>
<tr>
<th>Treatment</th>
<th>µM</th>
<th>IL-2</th>
<th>IL-6</th>
<th>TNFα</th>
<th>Cell number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mixture 1</td>
<td>1 µM</td>
<td>*</td>
<td>⬤</td>
<td>*</td>
<td>+401–500%</td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>*</td>
<td>⬤</td>
<td>*</td>
<td>+201–400%</td>
</tr>
<tr>
<td>Mixture 2</td>
<td>1 µM</td>
<td>*</td>
<td>⬤</td>
<td>*</td>
<td>+101–200%</td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>*</td>
<td>⬤</td>
<td>*</td>
<td>+30–100%</td>
</tr>
<tr>
<td>Mixture 3</td>
<td>1 µM</td>
<td>*</td>
<td>⬤</td>
<td>*</td>
<td>+6–29%</td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>*</td>
<td>⬤</td>
<td>*</td>
<td>0±5%</td>
</tr>
<tr>
<td>Mixture 4</td>
<td>1 µM</td>
<td>*</td>
<td>⬤</td>
<td>*</td>
<td>–6–19%</td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>*</td>
<td>⬤</td>
<td>*</td>
<td>–20–40%</td>
</tr>
<tr>
<td>Mixture 5</td>
<td>1 µM</td>
<td>*</td>
<td>⬤</td>
<td>*</td>
<td>–41–60%</td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>*</td>
<td>⬤</td>
<td>*</td>
<td>–61–80%</td>
</tr>
<tr>
<td>Mixture 6</td>
<td>1 µM</td>
<td>*</td>
<td>⬤</td>
<td>*</td>
<td>–81–100%</td>
</tr>
</tbody>
</table>

### Data Key

- +401–500%
- +201–400%
- +101–200%
- +30–100%
- +6–29%
- 0±5%
- –6–19%
- –20–40%
- –41–60%
- –61–80%
- –81–100%
number of dietary components including curcumin, resveratrol, and isorhamnetin. CD4+ T-lymphocytes at 1 µmol/l significantly reduced interferon-γ induced protein 10 (IP-10) release compared with the matched DMSO vehicle control (P < 0.05; one-way ANOVA with Dunnett's post hoc test). *Groups that significantly differed from the control group (one-way ANOVA with Dunnett's post hoc test; P < 0.05). There were no significant differences between groups for other cytokines. Data for the other cytokines are available in the Online Supplementary Fig. S2. LVC, LPS and vehicle control; 0.2 and 1 denote concentrations in µmol/l.

Fig. 5. Cytokine release by lymphocytes from a healthy donor following treatment for 24 h with the polyphenols resveratrol, isorhamnetin and curcumin with the addition of 20 ng/ml lipopolysaccharide (LPS) at the 5-h time point. Isorhamnetin at 1 µmol/l significantly reduced interferon-γ induced protein 10 (IP-10) release compared with the matched DMSO vehicle control (P < 0.05; one-way ANOVA with Dunnett's post hoc test). *Groups that significantly differed from the control group (one-way ANOVA with Dunnett's post hoc test; P < 0.05). There were no significant differences between groups for other cytokines. Data for the other cytokines are available in the Online Supplementary Fig. S2. LVC, LPS and vehicle control; 0.2 and 1 denote concentrations in µmol/l.

Production of H2O2 by (poly)phenols does not strongly correlate with cytokine release by CD4+ T-lymphocytes

Correlation assays were performed between the H2O2 production by test compounds and their effects on Jurkat CD4+ T-lymphocyte growth and pro-inflammatory cytokine release (Fig. 6(b)–(e)). These data indicate a potential correlation between H2O2 production and IL-8 release in non-PMA/PHA-stimulated cells (R² 0.3048).

Discussion

In these studies, we evaluated a panel of thirty-one (poly)phenols for potential anti-inflammatory activity using a human T-lymphocyte model of cytokine production. The compounds tested were grouped by their molecular weight (Fig. 2 & 3), as the lower molecular weight compounds tended to be the colonic catabolites (phenolic acids). We observed substantial inhibition of cytokine release primarily by the parent polyphenols, several of which modified cytokine release and proliferation by T-lymphocytes under both baseline and activated (PMA/PHA stimulated) conditions. We also investigated mixtures of (poly)phenols, and our data show that five of the six mixtures of test compounds had greater anti-inflammatory effects than that predicted under our null hypothesis based on the effects of the individual compounds. We further explored the effects of three of the dietary polyphenols showing anti-inflammatory effects in Jurkat cells in healthy human lymphocytes and found that isorhamnetin reduced pro-inflammatory cytokine release from LPS-stimulated lymphocytes at 1 µmol/l. (Poly)phenols have been proposed to reduce the risk of developing chronic diseases during ageing by modulating inflammatory responses and the production of pro-inflammatory cytokines in multiple tissues.

A number of previous studies have examined the potential effects of various polyphenols on cytokine release, and a number of dietary components including curcumin, resveratrol, genistein and epigallocatechin have been shown to modulate the release of pro-inflammatory cytokines from cells in culture. Various mechanisms of action have been proposed including inhibition of NF-κB, inhibition of prostanoids, inhibition of AMP-activated protein kinase (AMPK) and mitogen-activated protein kinase (MAPK) pathways and antioxidant effects. There has been a great deal of interest in the bioavailability of dietary polyphenols, as the non-metabolised compounds are only found in the circulation at ns to low µmol concentrations. Compounds such as flavonoids are absorbed in the small intestine and appear in the circulation as glucuronoids, sulphates and methylated metabolites, but these are rapidly removed from the bloodstream; however, substantial amounts of the unconjugated compounds pass into the colon where they are converted to lower molecular weight catabolites such as phenolic acids by colonic microflora. Relatively little is known about the potential anti-inflammatory effects of these lower molecular weight phenolic acids following absorption, and this was a major aim of the present study.

Polyphenols were routinely examined at final concentrations of either 1 or 30 µmol/l, reflecting concentrations that may potentially be achieved in the circulation through ingestion of foodstuffs or supplements, respectively. Our data showed that several (poly)phenol treatments modulated the release of pro-inflammatory cytokines (IL-2, IL-8 and TNFα) from Jurkat human CD4+ T-lymphocytes. The Jurkat cell line was originally derived from an adolescent male with acute lymphoblastic leukaemia and they are widely used as a model for pro-inflammatory cytokine release. Jurkat CD4+ T-lymphocytes were incubated with test compounds at 1 and 30 µmol either non-stimulated or stimulated with PMA/PHA. We were interested to investigate both lower and higher dose ranges based on previous reports of differential effects between low- and high-dose (poly)phenols in vivo. The most potent anti-inflammatory compounds from our experiments in Jurkat CD4+ T-lymphocytes were isorhamnetin (a flavonol that occurs as a glycoside in apples, onions and green tea), curcumin (from the Indian spice turmeric) and resveratrol (which is present in the skin of red, purple and black grapes and in especially high concentrations in Itadori tea).

The low molecular weight phenolic acids (Fig. 2) were generally less effective at reducing cytokine release than the unconjugated polyphenols, although some reductions in IL-2 release were seen with vanillic acid, tyrosol and 4-hydroxymandelic acid. Vanillic acid is a catabolite of multiple dietary polyphenols, including those found in wheat and blackcurrant juice, and is also present at high concentrations in acai berries. Vanillic acid significantly reduced IL-2 release from non-stimulated Jurkat CD4+ T-lymphocytes at 1 µmol/l, which is within the range of concentrations previously reported in human plasma, suggesting that vanillic acid may be a physiologically relevant anti-inflammatory metabolite of dietary polyphenols.

Following ingestion of (poly)phenol-rich foodstuffs, a range of (poly)phenols, conjugates and catabolites are absorbed into the circulation. It is not understood whether the exposure of CD4+ T-lymphocytes to mixtures of these compounds may elicit different responses in comparison with the same compounds applied individually. To begin to address this issue, we treated...
Jurkat CD4⁺ T-lymphocytes with six different mixtures of (poly)phenols. The mixtures of compounds used were selected as representative of low molecular weight colonic metabolites (mix 1), mid-molecular weight colonic catabolites (mix 2), dietary polyphenols (mix 3), polyphenols and high-molecular weight hydroxycinnamate metabolites (mix 4), hydroxycinnamate derivatives derived from chlorogenic acid produced after the consumption of coffee (mix 5) and compounds potentially derived from apples (mix 6). Of these, five mixtures reduced cytokine release more than that predicted based on the cumulative effects of individual compounds. In contrast, mixture 1 was found to be relatively pro-inflammatory and comprised low molecular weight catabolites that individually induced pro-inflammatory cytokine release. Thus, we speculate that there may be synergistic anti-inflammatory effects of some polyphenols when they are present in foodstuffs, and...
the data obtained generally support this. Demonstration of true synergy between bioactive materials such as drugs requires a rigorous statistical approach\(^{(39)}\), which we do not have the dose–response data to undertake for the large group of polyphenols that were studied; however, the data presented appear to indicate the possibility of such synergistic effects and warrant further investigation.

It has been reported that (poly)phenols produce H\(_2\)O\(_2\) in cell culture media due to autoxidation catalysed by transition metals such as Fe and Cu and that this may influence the responses of cells in culture\(^{(37,40)}\). We measured the production of H\(_2\)O\(_2\) by different (poly)phenols and related compounds in RPMI-1640 medium containing 10% FBS using the Amplex red-HRP technique. This assay is specific for H\(_2\)O\(_2\) in simple solutions and has been widely used to examine H\(_2\)O\(_2\) release by cells and sub-cellular fractions of cells\(^{(41)}\). H\(_2\)O\(_2\) generation was found to vary between compounds, with certain phenolic catecholates producing relatively large amounts of H\(_2\)O\(_2\) and others producing no detectable H\(_2\)O\(_2\). Analysis of H\(_2\)O\(_2\) generation by (poly)phenols in comparison with their chemical structures indicated that, in accordance with theoretical predictions\(^{(40)}\), molecules with orthohydroxy groups on adjacent carbons of a benzene ring tended to generate H\(_2\)O\(_2\). However, protocatechuic acid and 3-O-methylquercetin, which have benzene ring ortho-hydroxy groups, generated negligible H\(_2\)O\(_2\), and moderate H\(_2\)O\(_2\) generation was detected from isorhamnetin and resveratrol, which do not have orthohydroxy groups, implying that other aspects of the chemical structure also influence H\(_2\)O\(_2\) generation. The average rate of H\(_2\)O\(_2\) generation for these compounds in RPMI-1640 medium was 5-6 nmol H\(_2\)O\(_2\)/\(\mu\)mol (poly)phenol per min. We investigated whether H\(_2\)O\(_2\) generation by each test compound correlated with their effects on the release of IL-2, IL-8 or TNF\(_{\alpha}\) by Jurkat CD\(_4^+\) T-lymphocytes or the growth of Jurkat cultures. A correlation was identified between H\(_2\)O\(_2\) production and IL-8 release by CD\(_4^+\) T-lymphocytes that were not stimulated with PMA/PHA. Interestingly, previous studies have indicated that IL-8 production is subject to modulation by redox signalling\(^{(34)}\) and can be induced by extracellular H\(_2\)O\(_2\) in epithelial cell lines via activation of the redox-sensitive transcription factors activator protein-1 (AP-1) and NF-\(\kappa\)B\(^{(42,43)}\). Our results suggest that with PMA/PHA stimulation the influence of H\(_2\)O\(_2\) on IL-8 release appears to become negligible. IL-2 and TNF\(_{\alpha}\) release and cell proliferation showed no clear relationship with H\(_2\)O\(_2\) generation in non-stimulated or PMA/PHA-stimulated Jurkat CD\(_4^+\) T-lymphocytes. Halliwell et al\(^{(44,45)}\) have also pointed out that the absence of any detection of H\(_2\)O\(_2\) generation by a compound in cell culture cannot be equated to the stability of the compound as some polyphenols were observed to rapidly degrade and autoxidise in the absence of detectable H\(_2\)O\(_2\) generation. Thus, our studies indicate a lack of correlation between in vitro H\(_2\)O\(_2\) generation and effects of the compound on cytokine release, but do not exclude other cell culture artifacts that may have influenced the data obtained.

We chose to undertake a limited proof-of-principle study to investigate the potential anti-inflammatory effects of isorhamnetin, curcumin and resveratrol in primary PBMC-derived human lymphocytes. Cells were pre-treated with 1 or 30\(\mu\)mol polyphenol for 5 h, followed by stimulation of cytokine release using LPS stimulation and incubation for a total period of 24 h. We observed a significant reduction in IP-10 release following treatment with 1\(\mu\)mol isorhamnetin, and there was also a trend \((P=0.07)\) towards reduced TNF\(_{\alpha}\) release with the same treatment. These studies were undertaken using lymphocytes from a single donor and clearly require confirmation using cells from a larger group of donors, but this approach was considered out with the remit of the present study due to the large variability in cytokine release from lymphocytes obtained from different donors.

In conclusion, we have shown that (poly)phenols modulate the release of cytokines by Jurkat CD\(_4^+\) T-lymphocytes under resting and chemically activated conditions. Some compounds were found to have anti-inflammatory effects, while others were pro-inflammatory, and the effects varied with dose, suggesting that some dietary (poly)phenols may be beneficial for the prevention or management of chronic inflammatory conditions. We identified isorhamnetin, curcumin, resveratrol and vanillic acid as negative regulators of pro-inflammatory cytokine release in Jurkat CD\(_4^+\) T-lymphocytes, and also showed that 1\(\mu\)mol isorhamnetin reduced pro-inflammatory cytokine release by primary human lymphocytes. Use of mixtures of (poly)phenols also suggested that they may act synergistically to modulate cytokine release by Jurkat CD\(_4^+\) T-lymphocytes. Taking into account the main dietary sources of the compounds, our data support a potential anti-inflammatory role for (poly)phenols derived from red, purple and black grapes, turmeric, whole wheat, black-currants, apples and onions, and suggest that individuals at risk of chronic inflammation, such as older people, may benefit from supplementing their diets with isorhamnetin, resveratrol, curcumin and vanillic acid or with food sources that yield these bioactive molecules.

**Acknowledgements**

The authors are grateful to Melanie Sinclair for the excellent technical support.

This work was supported by a grant from the Biotechnology and Biological Sciences Research Council (BBSRC) through the BBSRC Diet Research Industry Club, grant no. BB/I005994/1. The funder had no role in the design, analysis or writing of this article.

M. J. J., A. M. A., A. C., S. B. L. and F. Mc. A. were involved in formulating the research question and designing the study; C. T. F. and S. R. carried out the study; C. T. F., S. R., M. J. J., A. M. A. and S. B. L. analysed the data; C. T. F. wrote the first draft of the manuscript; and all the authors edited the final version of the manuscript.

S. B. L. is employed by Unilever plc. None of the authors has any conflicts of interest to declare.

**Supplementary material**

For supplementary material\(\text{s}\) referred to in this article, please visit http://dx.doi.org/10.1017/S0007114516000805
References


